In contrast, seven other non-synonymous or frameshift mutations (in genes UGT3A2, PLCG1, OR10K1, COL9A1, MAGEA6, CNBD1 and LG14) were detected only in the metastatic tumor, indicating a selection and proliferative advantage of cells with the diverse genotype under sunitinib treatment. Here, OR10K1 is linked to metastatic neoplasm.